Application of delinearized ubiquitin enzyme family with sequence similarity 105, member B (FAM105B) to liver cancer diagnosis, treatment and prognosis judgment

Abstract

The invention provides application of delinearized ubiquitin enzyme family with sequence similarity 105, member B (FAM105B) in liver cancer diagnosis, treatment and prognosis judgment. Various technical detection finds that the FAM105B is highly expressed in a liver cancer cell line and liver cancer tissue, and high expression of the FAM105B is positively correlated with adverse clinical pathological characteristics of a hepatocellular carcinoma (HCC) patient, a poor postoperative overall survival rate and a poor tumor-free survival rate; it is proved that high expression of the FAM105B in theliver cancer tissue is an independent risk factor influencing long-term survival of liver cancer patients; an in-vitro hepatoma cell model constructed by gene knockout and overexpression techniques finds that the FAM105B can promote the proliferation, migration and invasion abilities and epithelial-mesenchymal transition of hepatoma cells. The research findings indicate that the delinearized ubiquitin enzyme FAM105B can be used as a marker for developing a new liver cancer diagnosis and prognosis judgment kit, and an effective target is provided for preparing liver cancer treatment medicines.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to the application of a potential liver cancer marker delinear ubiquitinase FAM105B in the diagnosis, treatment and prognosis judgment of liver cancer. Background technique [0002] Hepatocellular carcinoma (HCC, hereinafter referred to as liver cancer) is the main pathological type of primary liver cancer, one of the most common malignant tumors in the world, and ranks second in the cause of cancer-related death. Liver cancer has a high incidence rate, poor prognosis, and a serious threat to human life and health. It has long been a difficult problem in the medical field. [0003] In recent years, although the improvement of liver surgical treatment technology and the development of comprehensive treatment methods such as local treatment, molecular targeted therapy, and immunotherapy have increased the 5-year survival rate of patients with liver cancer, due to the limited indi...

AI Technical Summary

Problems solved by technology

In bone marrow-derived macrophages, the loss of FAM105B will lead to excessive production of Met1-linked ubiquitin chains, resulting in abnormal activation of NF-κB signaling and dysregulation of inflammatory cytokine secretion

However, whether FAM105B also participates in the regulation of the above-mentioned signaling pathways in liver cancer cells, and whether it plays a role in promoting the invasion and metastasis of liver cancer through the above-mentioned signaling pathways, needs further in-depth study.

Images